Northpond Ventures

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Eleanor Health is a provider of addiction and mental health services focused on delivering long-term recovery outcomes through a value-based care model. Founded in 2019 and headquartered in Waltham, Massachusetts, Eleanor offers comprehensive, whole-person care for mental health and substance misuse. The company operates a network of outpatient clinics and also provides virtual care as well as support in patients' homes and communities. Its services include medication-assisted treatment, evidence-based outpatient care, behavioral health services, and personalized recovery plans, all aimed at facilitating a faster recovery process for individuals suffering from substance abuse disorder.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Founded in Cambridge, Massachusetts in 2019 by Jifei Ou, OPT Industries specializes in precision-engineered products at the micron-scale. Utilizing vertically integrated machinery, software, and design expertise, they provide customers with high-volume production and shortened lead times.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Torus Biosystems is a biotechnology company founded in 2019 and based in Cambridge, Massachusetts. It specializes in the development of a diagnostic device that facilitates DNA testing for scientific and medical research applications. The company's apparatus is designed for use across various sectors, including consumer products, food safety for humans and animals, personal care, and agriculture. By providing accessible DNA testing solutions, Torus Biosystems aims to enhance the understanding of biochemical agents in both medical and non-medical contexts.

Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

NanoView Diagnostics develops the ExoView platform for characterizing extracellular vesicles through specific binding and detection on an affinity microarray. Its products include ExoView R100, ExoView Tetraspanin kits, custom assays, sample services, and support.

Emulate is a biotechnology company that develops organ-on-a-chip human emulation technology to model how diseases, medicines, chemicals, and foods affect human health. Its platform includes lung, intestinal, liver, and skin organ chips that reproduce normal biology and disease states, enabling human-relevant insights beyond traditional cell culture or animal models. The company also provides drug development tools and instrumentation software to support research and development workflows for researchers across biotechnology, pharmaceutical, consumer health, cosmetics, chemical, food, and agrochemical sectors, as well as government agencies and academic institutions. Founded in 2013 and headquartered in Boston, Emulate aims to accelerate understanding of human biology and improve human health outcomes.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.

908 Devices Inc. is a Boston-based company that specializes in the development and sale of handheld and desktop measurement devices for chemical and biochemical analysis. Founded in 2012, the company leverages mass spectrometry technology to create portable tools designed for immediate application in various fields, including life sciences research, bioprocessing, industrial biotechnology, and forensics. Its product lineup includes the MX908, a battery-powered, handheld mass spectrometry device capable of rapid analysis of unknown gas, liquid, and solid materials; the Rebel, a desktop analyzer offering real-time data on bioprocess environments; and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. 908 Devices aims to provide reliable and actionable insights in challenging environments, meeting the needs of professionals who require efficient solutions for complex analytical tasks.

Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

NanoView Diagnostics develops the ExoView platform for characterizing extracellular vesicles through specific binding and detection on an affinity microarray. Its products include ExoView R100, ExoView Tetraspanin kits, custom assays, sample services, and support.

SeLux Diagnostics, Inc. is a biotechnology company based in Charlestown, Massachusetts, focused on developing a next-generation phenotyping platform for antibiotic susceptibility testing and diagnostics of infectious diseases. Established in 2014, the company utilizes synthetic amplifier technology to enhance the speed and complexity of antibiotic susceptibility testing, thereby significantly improving patient care. By facilitating the rapid selection of personalized antimicrobial therapies, SeLux aims to transform the management of infectious diseases, ultimately saving lives, reducing hospital stays, and combating the growing issue of antibiotic resistance through more targeted treatments.

Founded in 2017, Outcomes4Me is a Boston-based company that empowers cancer patients through its AI-driven platform. This platform provides personalized, evidence-based treatment options and real-time clinical information, enabling patients to navigate their care effectively and improve outcomes.